Patents Assigned to Theratechnologies Inc.
-
Publication number: 20230036041Abstract: The present disclosure relates to compositions comprising a solubilizing agent and a peptide compound and/or a conjugate compound, processes, methods and uses thereof for treatment of cancer or aggressive cancer.Type: ApplicationFiled: December 7, 2020Publication date: February 2, 2023Applicant: THERATECHNOLOGIES INC.Inventors: Christian MARSOLAIS, Michel DEMEULE, Jean-Christophe CURRIE, Alain LAROCQUE
-
Patent number: 9334314Abstract: Peptide compounds derived from human melanotransferrin, and compositions thereof, are described. Uses of these peptide compounds, for example to modulate angiogenesis and/or cell migration, and/or to treat angiogenesis-related disorders (e.g., cancer), are also described.Type: GrantFiled: October 18, 2012Date of Patent: May 10, 2016Assignee: THERATECHNOLOGIES INC.Inventors: Richard BĂ©liveau, Jonathan Michaud-Levesque, Krishna G. Peri, Abdelkrim Habi, Nathalie Bousquet-Gagnon
-
Patent number: 9073963Abstract: The invention relates to compositions which are useful for inhibiting prostaglandin F2? receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.Type: GrantFiled: April 15, 2009Date of Patent: July 7, 2015Assignees: Universite De Montreal, Theratechnologies, Inc.Inventors: Krishna Peri, Felix Polyak, William Lubell, Eryk Thouin, Sylvain Chemtob
-
Patent number: 8871713Abstract: Stabilized solid and liquid pharmaceutical formulations comprising a GRF molecule as active ingredient, such as GRF analogs including those comprising an N-terminal-attached hydrophobic moiety, such as [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises a GRF molecule or a pharmaceutically acceptable salt thereof and a ?-cyclodextrin which is not conjugated to the GRF molecule or salt thereof. Also disclosed is the use of the formulation for the treatment of various conditions, methods of preparing the formulation, as well as kits containing it. Methods of stabilizing (e.g., with respect to chemical stability) such GRF molecules, as well as methods of inhibiting their deamidation at Asn8, are also disclosed.Type: GrantFiled: March 14, 2013Date of Patent: October 28, 2014Assignee: Theratechnologies Inc.Inventors: Kirill I Shingel, Daniel Fleury
-
Publication number: 20140249083Abstract: Stabilized solid and liquid pharmaceutical formulations comprising a GRF molecule as active ingredient, such as GRF analogs including those comprising an N-terminal-attached hydrophobic moiety, such as [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises a GRF molecule or a pharmaceutically acceptable salt thereof and a ?-cyclodextrin which is not conjugated to the GRF molecule or salt thereof. Also disclosed is the use of the formulation for the treatment of various conditions, methods of preparing the formulation, as well as kits containing it. Methods of stabilizing (e.g., with respect to chemical stability) such GRF molecules, as well as methods of inhibiting their deamidation at Asn8, are also disclosed.Type: ApplicationFiled: March 14, 2013Publication date: September 4, 2014Applicant: THERATECHNOLOGIES INC.Inventors: Kirill I Shingel, Daniel Fleury
-
Patent number: 8822413Abstract: A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and/or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).Type: GrantFiled: July 7, 2008Date of Patent: September 2, 2014Assignee: Theratechnologies Inc.Inventors: Krishna G. Peri, Abdelkrim Habi
-
Publication number: 20130302909Abstract: Improved methods for determining normal IGF-1 levels in HIV infected subjects, based on a determination of the log of IGF-1 values obtained in blood-derived samples from a population of HIV-infected subjects, are disclosed. Also disclosed are methods of determining whether a given HIV-infected subject exhibits a normal IGF-1 level, based on a comparison of either the IGF-1 value or the log of the IGF-1 value obtained from a blood-derived sample of the subject with a normative IGF-1 range determined using the exponentiation of the log of IGF-1 values or the log of IGF-values obtained in blood-derived samples from a population of age- and gender-matched HIV-infected subjects. Such methods are useful for example to monitor GH stimulation therapy in HIV-infected subjects.Type: ApplicationFiled: January 11, 2012Publication date: November 14, 2013Applicant: THERATECHNOLOGIES INC.Inventor: Diane Potvin
-
Patent number: 8481489Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: September 26, 2008Date of Patent: July 9, 2013Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
-
Patent number: 8435945Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: September 26, 2008Date of Patent: May 7, 2013Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
-
Patent number: 8361964Abstract: Novel GRF analogs having GRF activity are described herein, as well as uses thereof for example as a GRF receptor agonist, e.g., to induce growth hormone secretion in a subject or biological system.Type: GrantFiled: April 17, 2012Date of Patent: January 29, 2013Assignee: Theratechnologies Inc.Inventors: Krishna G. Peri, Abdelkrim Habi
-
Patent number: 8314066Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: October 23, 2007Date of Patent: November 20, 2012Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
-
Publication number: 20120270784Abstract: Novel GRF analogs having GRF activity are described herein, as well as uses thereof for example as a GRF receptor agonist, e.g., to induce growth hormone secretion in a subject or biological system.Type: ApplicationFiled: April 17, 2012Publication date: October 25, 2012Applicant: THERATECHNOLOGIES INC.Inventors: Krishna G. Peri, Abdelkrim Habi
-
Publication number: 20120004174Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: July 7, 2011Publication date: January 5, 2012Applicant: THERATECHNOLOGIES INC.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Publication number: 20110105390Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.Type: ApplicationFiled: January 11, 2011Publication date: May 5, 2011Applicant: Theratechnologies Inc.Inventors: Bruno LUSSIER, Luc Vachon, Soraya Allas, Thierry Abribat
-
Publication number: 20100267636Abstract: Combination therapies comprising a drug metabolized by cytochrome P450 and a growth hormone (GH)-inducing compound (such as a GRF molecule) are described, in which there are no or substantially no drug interactions.Type: ApplicationFiled: April 20, 2010Publication date: October 21, 2010Applicant: THERATECHNOLOGIES INC.Inventor: CHRISTIAN MARSOLAIS
-
Publication number: 20100087366Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: September 26, 2008Publication date: April 8, 2010Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Publication number: 20090253623Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: September 26, 2008Publication date: October 8, 2009Applicant: THERATECHNOLOGIES INC.Inventors: THIERRY ABRIBAT, ANDRE DE VILLERS, ALCIDE CHAPDELAINE, SORAYA ALLAS, DENIS GRAVEL
-
Patent number: 7538185Abstract: Novel GLP-1 analogs having improved biological potency as well as extended pharmacological activity are described herein. More specifically, the present invention relates to GLP-1 analogs (28 or 29 aa long) comprising amino acid substitutions at one or more of the following positions: 8, 20, 27, 30 and 33.Type: GrantFiled: January 7, 2005Date of Patent: May 26, 2009Assignee: Theratechnologies Inc.Inventors: Krishna Peri, Daniel Abran, Abdelkrim Habi
-
Patent number: 7521530Abstract: The invention relates to compositions which are useful for inhibiting prostaglandin F2?receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.Type: GrantFiled: June 11, 2002Date of Patent: April 21, 2009Assignees: Universite De Montreal, Theratechnologies, Inc.Inventors: Krishna Peri, Felix Polyak, William Lubell, Eryk Thouin, Sylvain Chemtob
-
Publication number: 20090088383Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: September 26, 2008Publication date: April 2, 2009Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdlaine